Recent Updates
Recently added Catalysts
ARGX Positive Sentiment Score: 60/100

argenx Announces Results of Annual General Meeting of Shareholders

Wednesday, May 28, 2025 2 min read
Key Takeaway: argenx SE announced the results of its Annual General Meeting of shareholders, held on May 27, 2025. A total of 91.1% of the company's share capital was represented. Most agenda items received majority approval, excluding the remuneration policy, which fell short of the required majority. This outcome suggests mixed sentiments among shareholders regarding executive compensation.

Market Sentiment Analysis

POSITIVE FACTORS

  • 91.1% of share capital was represented at the meeting, indicating strong shareholder engagement.
  • All items on the agenda were approved except one, reflecting overall positive governance.
  • Partnerships with leading researchers demonstrate a commitment to innovation in immunology.

CONCERNS & RISKS

  • The remuneration policy item did not receive the required 75% majority vote, which may raise concerns.
  • A lack of unanimous approval could indicate potential dissent among shareholders.

Full Press Release Details

argenx Announces Results of Annual
General Meeting of Shareholders
May 28, 2025 - 10:01 PM CET
the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives
of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held on May 27,
91.1% of the Company's share
capital was represented at the Annual General Meeting.
All items on the agenda received
the required majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). This agenda item received a 73.0%
majority where a 75% majority was required.
As part of the approved resolutions:
The voting result and all documents relating
to the shareholders' meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.
is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with
leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into
a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor
(FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental
Instagram, Facebook, and YouTube.
further information, please contact:

Frequently Asked Questions

What percentage of shares were represented at the meeting?

91.1% of the share capital was represented at the Annual General Meeting.

Which agenda item did not achieve the required majority?

Agenda item 5 regarding the remuneration policy did not meet the majority.

What is argenx focused on improving?

argenx is committed to improving lives affected by severe autoimmune diseases.

Where can meeting documents be accessed?

Documents related to the meeting are available on the argenx website.

Tags: ARGX Viatris Investor Conferences Healthcare argenx shareholders meeting immunology remuneration policy autoimmune diseases
Last updated: May 28, 2025